Pratyria

Patient Information Leaflet

Pratyria, 75 mg, prolonged-release injectable suspension in a prefilled syringe
Pratyria, 100 mg, prolonged-release injectable suspension in a prefilled syringe
Pratyria, 150 mg, prolonged-release injectable suspension in a prefilled syringe
Initiation pack
Pratyria, 150 mg, prolonged-release injectable suspension in a prefilled syringe
Pratyria, 100 mg, prolonged-release injectable suspension in a prefilled syringe
Paliperidone
Please read all of this leaflet carefully before you start using this medicine, as it contains
important information for you.

• Keep this leaflet, as you may need to read it again.
• If you have any further questions, please ask your doctor, pharmacist, or nurse.
• If you experience any side effects, including any not listed in this leaflet, please tell your doctor, pharmacist, or nurse. See section 4.

Leaflet Contents

1. What Pratyria is and what it is used for
2. What you need to know before using Pratyria
3. How to use Pratyria
4. Possible side effects
5. How to store Pratyria
6. Contents of the pack and other information

1. What Pratyria is and what it is used for

Pratyria contains the active substance paliperidone, which belongs to a group of medicines called antipsychotics.
It is used for the maintenance treatment of symptoms of schizophrenia in adult patients who have already been stabilized on paliperidone or risperidone.
For patients who previously responded to oral paliperidone or risperidone and whose psychotic symptoms are mild to moderate, your doctor may consider initiating treatment with Pratyria without prior stabilization with paliperidone or risperidone.
Schizophrenia is a disorder with "positive" and "negative" symptoms. Positive symptoms mean the presence of symptoms that usually do not occur. For example, a person with schizophrenia may hear voices or see things that are not there (hallucinations), believe in things that are not true (delusions), or be excessively suspicious of others. Negative symptoms refer to the absence of usual behaviors or emotions. For example, a person with schizophrenia may appear withdrawn, emotionally flat or unresponsive, or may have difficulty speaking in a clear and logical way. People with this condition may also experience depression, anxiety, feelings of guilt, or tension.
Pratyria helps to reduce the symptoms of the illness and helps prevent their recurrence.

2. Important information before using Pratyria

When NOT to use Pratyria

• If the patient is allergic to paliperidone or any of the other ingredients of this medicine (listed in section 6).
• If the patient is allergic to another antipsychotic medicine, including the substance risperidone.

Warnings and precautions
Before starting treatment with Pratyria, discuss this with your doctor, pharmacist, or nurse.
The use of this medicine in elderly patients with dementia has not been studied. However, in such patients treated with other similar medicines, an increased risk of stroke or death has been observed (see section 4, Possible side effects).
All medicines have side effects, and some of the side effects of this medicine may worsen symptoms of other medical conditions. Therefore, during treatment with this medicine, discuss with your doctor if any of the following conditions apply:

• if the patient has Parkinson's disease
• if the patient has ever been diagnosed with a condition characterized by high fever and muscle stiffness (also known as neuroleptic malignant syndrome)
• if the patient has ever experienced abnormal movements of the tongue or facial muscles (tardive dyskinesia)
• if the patient has previously had a low white blood cell count (whether or not caused by other medicines)
• if the patient has diabetes or is predisposed to developing it
• if the patient has breast cancer or a pituitary gland tumor
• if the patient has heart disease or is being treated for heart conditions that may predispose to hypotension
• if the patient has low blood pressure upon sudden change to standing or sitting position
• if the patient has epilepsy
• if the patient has kidney function disorders
• if the patient has liver function disorders
• if the patient experiences prolonged and/or painful erection
• if the patient has problems with body temperature regulation or overheating
• if the patient has abnormally increased levels of prolactin hormone in the blood or suspicion of a prolactin-dependent tumor
• if the patient or their family has a history of blood clots in blood vessels, as antipsychotic medicines are associated with their development.

If any of the above criteria apply, the patient should consult their doctor, who may adjust the dose or perform periodic monitoring.

• The treating physician may order a white blood cell count test, as very rarely, dangerously low levels of a certain type of white blood cells necessary to fight infections have been observed in patients taking this medicine.
• Even if the patient previously tolerated oral paliperidone or risperidone, allergic reactions may rarely occur after injections of Pratyria. Seek immediate medical help if the patient develops rash, throat swelling, itching, or difficulty breathing, as these may be symptoms of a severe allergic reaction.
• This medicine may cause weight gain. Significant weight gain may negatively affect the patient's health. The treating physician will regularly monitor the patient's body weight.
• The treating physician will monitor for symptoms of elevated blood sugar levels, as new-onset diabetes or worsening of pre-existing diabetes has been observed in patients taking this medicine. In patients with pre-existing diabetes, blood glucose levels should be monitored regularly.
• Since this medicine may suppress vomiting, it may mask the body's normal response to ingestion of toxic substances or other medical conditions.
• During cataract removal surgery, the pupil (the black circle in the center of the eye) may not dilate sufficiently. Also, the iris (the colored part of the eye) may be flaccid during surgery, which may lead to eye damage. If the patient has planned eye surgery, inform the ophthalmologist about taking this medicine.

Children and adolescents
This medicine is not used in individuals under 18 years of age.
Pratyria and other medicines
Tell your doctor about all medicines currently taken or recently used by the patient, as well as any medicines the patient plans to use.

• Taking this medicine together with carbamazepine (an antiepileptic and mood stabilizer) may require adjustment of the Pratyria dose.
• Since this medicine acts primarily in the brain, combining it with other medicines such as other psychotropic medicines, opioids, antihistamines, and sedatives that act in the brain may increase side effects such as drowsiness or other effects on the brain.
• This medicine may cause low blood pressure; therefore, caution is advised when using it together with other medicines that lower blood pressure.
• This medicine may reduce the effectiveness of medicines used in Parkinson's disease and restless legs syndrome (e.g., levodopa).
• This medicine may cause abnormalities in the electrocardiogram (ECG), manifesting as prolongation of the electrical impulse through a specific part of the heart (known as "QT interval prolongation"). Other medicines with this effect include medicines used to regulate heart rhythm or treat infections, as well as other antipsychotics.
• If the patient is prone to seizures, this medicine may increase the risk of their occurrence. Other medicines with this effect include some medicines used to treat depression or infections, as well as other antipsychotics.
• Caution is advised when using Pratyria together with medicines that increase central nervous system activity (psychostimulants such as methylphenidate). Using Pratyria with alcohol Alcohol consumption should be avoided.

Pregnancy and breastfeeding
If the patient is pregnant or breastfeeding, suspects she may be pregnant, or plans to have a child, she should consult her doctor or pharmacist before using this medicine.
Pregnancy
This medicine should not be used during pregnancy unless discussed with a doctor.
Newborns whose mothers took paliperidone during the third trimester (last 3 months of pregnancy) may experience the following symptoms: tremors, muscle stiffness and/or weakness, drowsiness, agitation, breathing difficulties, and feeding problems. If such symptoms are observed in the child, contact a doctor.
Breastfeeding
This medicine may pass from the mother's body into the child through breast milk and harm the child. Therefore, breastfeeding should not be performed during treatment with this medicine.
Driving and operating machinery
During treatment with this medicine, dizziness, extreme tiredness, and vision disturbances may occur (see section 4). These effects should be taken into account in situations requiring full alertness, such as driving or operating machinery.
Pratyria contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per dose, meaning the medicine is considered "sodium-free".

3. How to use Pratyria

The medicine is administered by a doctor or other healthcare professional. Your doctor will inform you when the next injection is due. It is important not to miss a scheduled dose. If you are unable to keep the scheduled appointment, you must inform your doctor immediately so that a new appointment can be arranged as soon as possible.

Dosage and method of administration

The first (150 mg) and second (100 mg) injections of this medicine will be given into the upper arm, approximately one week apart. Afterwards, an injection (at a dose ranging from 25 mg to 150 mg) will be administered into the upper arm or buttock once a month.

If your doctor decides to switch you from long-acting risperidone injections to this medicine, the first injection of this medicine (at a dose ranging from 25 mg to 150 mg) will be given into the upper arm or buttock on the day of your next scheduled injection. Afterwards, an injection (at a dose ranging from 25 mg to 150 mg) will be administered into the upper arm or buttock once a month.

Depending on the symptoms present, your doctor may increase or decrease the administered dose by one level during the scheduled monthly injection.

Patients with renal impairment

Your doctor will adjust the dose of the medicine based on kidney function. If you have mild renal impairment, your doctor may reduce the dose. This medicine should not be used in cases of moderate or severe renal impairment.

Elderly patients

Your doctor may reduce the dose of the medicine if you have impaired kidney function.

Use of a higher than recommended dose of Pratyria

This medicine will be administered under medical supervision, so overdose is unlikely.

In patients who have received an excessive dose of paliperidone, the following symptoms may occur: drowsiness and sedation, increased heart rate, low blood pressure, abnormal ECG (electrocardiogram) findings, or slowed or abnormal movements of the face, body, arms, or legs.

Discontinuation of Pratyria

If you stop receiving the injections, the medicine will stop working. Do not discontinue treatment unless instructed by your doctor, as symptoms of the illness may return.

If you have any further questions about the use of this medicine, consult your doctor or pharmacist.

4. Possible adverse reactions

Like all medicines, this medicine can cause adverse reactions, although not everyone will experience them.
You should immediately inform your doctor if:

• the patient develops blood clots in the veins, especially in the legs (symptoms include swelling, pain and redness of the leg), which may travel through blood vessels to the lungs, causing chest pain and difficulty breathing. If such symptoms occur, seek immediate medical help.
• in a patient with dementia, there is a sudden change in mental state or sudden weakness or numbness of the face, arms or legs, particularly on one side, or speech disturbances, even if brief. These symptoms may indicate a stroke.
• fever, muscle stiffness, sweating or reduced level of consciousness occurs (a condition called neuroleptic malignant syndrome). Immediate treatment may be necessary.
• a man experiences prolonged or painful erection. This condition is known as priapism. Immediate treatment may be required.
• involuntary rhythmic movements of the tongue, lips or face occur. Discontinuation of paliperidone treatment may be necessary.
• a severe allergic reaction occurs characterized by: fever, swelling of lips, face, tongue or throat, shortness of breath, itching, skin rash, and sometimes low blood pressure (referred to as "anaphylactic reaction"). Even if the patient previously tolerated risperidone or paliperidone taken orally, allergic reactions may rarely occur after paliperidone injections.
• the patient is scheduled for eye surgery, the ophthalmologist should be informed about taking this medicine. During cataract removal surgery, floppy iris syndrome may occur, which could lead to eye damage.
• the patient has a dangerously low number of certain white blood cells essential for fighting infections. The following adverse reactions may occur:

Very common adverse reactions: may affect more than 1 in 10 patients

• difficulty falling asleep or waking up

Common adverse reactions: may affect less than 1 in 10 patients

• cold symptoms, urinary tract infection, flu-like symptoms
• the medicine Pratyria may increase prolactin hormone levels in the blood (which may, but does not necessarily, cause symptoms). If symptoms of elevated prolactin occur, they may include (in men): breast swelling, difficulty achieving or maintaining erection or other sexual disturbances. In women, they may include breast discomfort, milk discharge from the breasts, absence of menstrual bleeding or other menstrual cycle disturbances
• high blood sugar levels, weight gain, weight loss, decreased appetite
• irritability, depression, anxiety
• parkinsonism: this condition may include slow or abnormal movements, feelings of stiffness or muscle tension (causing uneven movements), and sometimes even a sensation of "freezing" of movements followed by release. Other symptoms of parkinsonism include: slow shuffling gait, resting tremor, increased salivation and (or) drooling and expressionless face
• psychomotor restlessness, feeling of drowsiness or reduced alertness
• dystonia: this condition involves slow or sustained involuntary muscle contractions. Although it may affect any part of the body (possibly resulting in abnormal body posture), dystonia most commonly affects facial muscles, including abnormal eye, mouth, tongue or jaw movements
• dizziness
• dyskinesia: this condition involves involuntary muscle movements and may manifest as repetitive, spasmodic or twisting movements or jerks
• tremor
• headache
• fast heart rate
• high blood pressure
• cough, stuffy nose
• abdominal pain, vomiting, nausea, constipation, diarrhoea, indigestion, toothache
• increased liver enzyme activity in blood
• bone or muscle pain, back pain, joint pain
• absence of menstruation
• fever, weakness, fatigue
• injection site reaction, including itching, pain or swelling

Uncommon adverse reactions: may affect less than 1 in 100 patients

• pneumonia, bronchitis, respiratory tract infections, sinus infection, bladder infection, ear infection, fungal nail infection, tonsillitis, skin infection
• decreased number of white blood cells, decreased number of certain white blood cells protecting against infections, anaemia
• allergic reaction
• onset of diabetes and worsening of pre-existing diabetes, increased blood insulin levels (hormone regulating blood sugar levels)
• increased appetite
• loss of appetite leading to malnutrition and low body weight
• high blood triglyceride (fat) levels, increased blood cholesterol levels
• sleep disturbances, elevated mood (mania), decreased libido, nervousness, nightmares
• tardive dyskinesia (jerky or twitching uncontrolled movements of the face, tongue or other body parts). Inform your doctor immediately if involuntary rhythmic movements of the tongue, lips or face occur. Discontinuation of this medicine may be necessary
• fainting, need to move body parts, dizziness upon standing up, concentration difficulties, speech disturbances, loss or altered sense of taste, reduced sensitivity to pain and touch on the skin, tingling, pricking or numbness of the skin
• blurred vision, eye infection or conjunctivitis, dry eyes
• sensation of dizziness, ringing in the ears, ear pain
• heart conduction block between chambers, abnormal electrical conduction in the heart, QT interval prolongation on ECG, rapid heartbeat upon standing, slow heart rate, abnormal ECG recording, palpitations (awareness of heart beating)
• low blood pressure, low blood pressure upon standing (as a result, some patients taking this medicine may faint, feel dizzy or lose consciousness when standing up suddenly or rising)
• shortness of breath, sore throat, nosebleed
• abdominal discomfort, stomach or intestinal infection, difficulty swallowing, dry mouth
• excessive passing of gas
• increased GGTP enzyme activity (liver enzyme - gamma-glutamyl transferase) in blood, increased liver enzyme activity in blood
• hives, itching, rash, hair loss, skin eruption, dry skin, skin redness, acne, subcutaneous abscess
• increased CPK (creatine phosphokinase) enzyme activity in blood, an enzyme sometimes released from damaged muscles
• muscle cramps, joint stiffness, muscle weakness
• urinary incontinence (uncontrolled), frequent urination, painful urination
• erectile dysfunction, ejaculation disorders, absence of menstruation and other menstrual cycle disturbances (women), breast enlargement in men, sexual disturbances, breast pain, milk discharge from the breasts
• swelling of face, lips, eyes or mouth, body swelling, upper or lower limbs swelling
• increased body temperature
• change in gait
• chest pain, chest discomfort, general malaise
• skin hardening
• fall

Rare adverse reactions: may affect less than 1 in 1,000 patients

• eye infection
• skin inflammation caused by mites, scaly, itchy skin of the head or other body parts
• increased number of eosinophils (a type of white blood cells) in blood
• decreased number of platelets (blood cells which help stop bleeding)
• head tremor
• abnormal secretion of hormone regulating urine volume
• glucose in urine
• life-threatening complications of untreated diabetes
• low blood sugar levels
• excessive water drinking
• lack of movement and response to stimuli in a patient who is not asleep (catatonia)
• confusion
• sleepwalking (somnambulism)
• lack of emotions
• inability to achieve orgasm
• neuroleptic malignant syndrome (confusion, reduced or loss of consciousness, high fever and severe muscle rigidity), cerebrovascular disorders including sudden interruption of blood flow to the brain (stroke or "mini" stroke), lack of response to stimuli, loss of consciousness, low level of consciousness, seizures, balance disturbances
• abnormal motor coordination
• glaucoma (increased pressure inside the eyeball)
• eye movement disorders, rotary eye movements, light sensitivity, increased tearing, eye redness
• atrial fibrillation (irregular heartbeat), irregular heart rhythm
• blood clot in the lungs causing chest pain and breathing difficulties. If any of these symptoms occur, contact your doctor immediately
• blood clots in veins, particularly in the lower limbs (symptoms include swelling, pain and redness of the lower limbs). If such symptoms occur, contact your doctor immediately
• flushing attacks
• breathing disturbances during sleep (sleep apnoea)
• pulmonary congestion, respiratory tract hyperaemia
• crackling sounds in the lungs, wheezing
• pancreatitis, tongue swelling, faecal incontinence, very hard stool
• intestinal obstruction
• chapped lips
• drug-related skin rash, skin thickening, psoriasis
• muscle fibre breakdown and muscle pain (rhabdomyolysis)
• joint swelling
• inability to urinate
• breast discomfort, enlargement of breast glands, breast enlargement
• vaginal discharge
• priapism (prolonged erection which may require surgical intervention)
• very low body temperature, chills, feeling of thirst
• withdrawal symptoms
• pus accumulation due to infection at injection site, deep skin infection, cyst at injection site, bruising at injection site

Adverse reactions with unknown frequency: frequency cannot be estimated from available data

• dangerously low number of certain white blood cells responsible for fighting infections;
• severe allergic reaction characterized by fever, swelling of lips, face, tongue or throat, shallow breathing, itching, skin rash, and sometimes low blood pressure
• dangerously excessive water drinking
• sleep-related eating disorders
• coma due to uncontrolled diabetes
• reduced oxygenation of various body parts (due to reduced blood flow)
• rapid, shallow breathing, aspiration pneumonia, voice disturbances
• lack of intestinal peristalsis leading to obstruction
• yellowing of the skin and eyes (jaundice)
• severe or life-threatening blistering rash with skin peeling, which may appear in the mouth, nose, eyes and genital areas and around these sites, and may also spread to other body parts (Stevens-Johnson syndrome or toxic epidermal necrolysis)
• severe allergic reaction with swelling, which may involve the larynx and lead to breathing difficulties
• skin depigmentation
• abnormal body posture
• in newborns whose mothers used Pratyria during pregnancy, adverse reactions to the medicine and (or) withdrawal symptoms may occur, such as: irritability, slow or sustained muscle contractions, tremor, drowsiness, breathing difficulties and feeding problems
• low body temperature
• necrosis at injection site and ulcer at injection site

Reporting of adverse reactions
If any adverse reactions occur, including any not listed in this leaflet, inform your doctor, pharmacist or nurse. Adverse reactions can be reported directly to the Department of Monitoring Adverse Drug Reactions, Office for Registration of Medicinal Products, Medical Devices and Biocidal Products: Al. Jerozolimskie 181C 02-222 Warsaw
Tel.: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Adverse reactions can also be reported to the marketing authorisation holder.
Reporting adverse reactions helps provide more information on the safety of this medicine.

5. How to store the medicine Pratyria

Keep the medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the cardboard box and
cartridge-syringe. The expiry date (EXP) refers to the last day of the stated month.
No special storage instructions are required for this medicine.
Medicines must not be disposed of via wastewater or household waste. Ask your
pharmacist how to dispose of medicines no longer in use. This will help protect
the environment.

6. Contents of the pack and other information

What Pratyria contains
The active substance is paliperidone.
Each pre-filled syringe of Pratyria 75 mg contains paliperidone palmitate equivalent to 75 mg of paliperidone.
Each pre-filled syringe of Pratyria 100 mg contains paliperidone palmitate equivalent to 100 mg of paliperidone.
Each pre-filled syringe of Pratyria 150 mg contains paliperidone palmitate equivalent to 150 mg of paliperidone.
The other ingredients are:
Polysorbate 20 (E 432)
Macrogol 4000
Citric acid monohydrate (E330)
Disodium hydrogen phosphate anhydrous (E 339)
Sodium dihydrogen phosphate monohydrate
Sodium hydroxide (E 542) (for pH adjustment)
Water for injections

What Pratyria looks like and contents of the pack
Pratyria is a white to off-white injectable suspension for extended release, supplied in a pre-filled syringe.
The pre-filled syringe is made of cyclic olefin copolymer, with a bromobutyl rubber stopper (plunger tip), a lock, and a "tip-cap" needle shield.
Each single pack contains: 1 pre-filled syringe and 2 needles.
Each starter pack contains:

• 1 pack of Pratyria 150 mg, 1 pre-filled syringe and 2 needles (administered on day 1 of treatment)
• 1 pack of Pratyria 100 mg, 1 pre-filled syringe and 2 needles (administered on day 8 of treatment)

Not all pack sizes may be marketed.

Marketing Authorisation Holder
STADA Arzneimittel AG,
Stadastrasse 2-18,
61118 Bad Vilbel,
Germany

Manufacturer/Importer
STADA Arzneimittel AG,
Stadastrasse 2-18,
61118 Bad Vilbel,
Germany
Stada Arzneimittel GmbH
Muthgasse 36/2, Doebling
1190 Vienna,
Austria

For further information about this medicinal product, contact the local representative of the Marketing Authorisation Holder:
STADA Pharm Sp. z o.o.
ul. Krakowiaków 44
02-255 Warsaw
Tel. +48 22 737 79 20

Pack with needle featuring Magellan safety protection

Information intended exclusively for medical or healthcare personnel, which should be read together with the full product information (Summary of Product Characteristics).

The injectable suspension is for single use only. Before administration, inspect visually for the presence of foreign particles. If foreign particles are observed in the prefilled syringe, do not use the medicinal product.

The package contains one prefilled syringe and two safety needles (22G x 1½ inches [38 mm x 0.7 mm] and 23G x 1 inch [25 mm x 0.6 mm]) for intramuscular administration.

1. Shake the prefilled syringe vigorously for at least 10 seconds to ensure homogeneity of the suspension.

2. Select the appropriate needle.

The first initiating dose of the medicinal product Pratyria (150 mg) should be administered on day 1 of treatment into the DELTOID MUSCLE using the DELTOID MUSCLE needle. The second initiating dose of the medicinal product Pratyria (100 mg) should be administered one week later (on day 8) also into the DELTOID MUSCLE using the DELTOID MUSCLE needle.

If switching from long-acting risperidone injections to the medicinal product Pratyria, the first injection of Pratyria (at a dose ranging from 25 mg to 150 mg) may be administered into the DELTOID MUSCLE or GLUTEAL MUSCLE using the appropriate needle on the day of the next scheduled injection.

Subsequently, monthly maintenance doses may be administered into either the DELTOID MUSCLE or GLUTEAL MUSCLE, using the appropriate needle.

For intramuscular injections into the DELTOID MUSCLE in patients with body weight <90 kg, use a 1-inch, 23G needle (25 mm x 0.6 mm) (needle with blue hub). If the patient's body weight is ≥90 kg, use a 1½-inch, 22G needle (38 mm x 0.7 mm) (needle with gray hub).

For intramuscular injections into the GLUTEAL MUSCLE, use a 1½-inch, 22G needle (38 mm x 0.7 mm) (needle with gray hub).

3. Hold the syringe with the tip pointing upward and remove the rubber cap with a gentle twisting motion.

4. Partially peel open the outer part of the blister packaging of the safety needle. Hold the needle sheath through the plastic packaging. Keep the syringe upright. Attach the safety needle to the syringe by gently screwing it on to avoid breakage or damage to the needle tip. Before administration, always check for any signs of damage or leakage.

5. Remove the needle cap with a straight pull. Do not twist the cap, as this may loosen the needle from the prefilled syringe.

6. Remove air from the prefilled syringe by gently pressing the plunger while holding the syringe in an upright position.

7. Inject the entire contents of the prefilled syringe intramuscularly, slowly and deeply, into the selected patient muscle—either deltoid or gluteal. Do not administer the medicinal product intravenously or subcutaneously.

8. After completing the injection, activate the needle safety mechanism by pressing the thumb or finger of one hand against the safety shield (8a, 8b) or against a flat surface (8c). A clicking sound indicates successful activation of the needle safety feature. Dispose of the prefilled syringe with the attached needle appropriately.

Any unused portions of the product or waste materials should be disposed of in accordance with local regulations.

Packaging with Terumo safety needle

Information intended exclusively for medical or healthcare personnel, and must be read together with the full product information (Summary of Product Characteristics).

The injectable suspension is for single use only. Before administration, inspect the suspension for foreign particles. If foreign particles are visible in the prefilled syringe, do not use the medicinal product.

The package contains one prefilled syringe and two safety-protected needles (22G x 1½ inches [38 mm x 0.7 mm] and 23G x 1 inch [25 mm x 0.6 mm]) for intramuscular administration.

1. Shake the prefilled syringe vigorously for at least 10 seconds to ensure homogeneity of the suspension.

2. Select the appropriate needle.

For injections into the DELTOID MUSCLE:

• For patients with body weight <90 kg, use the 1-inch, 23G needle (needle with blue hub).
• For patients with body weight ≥90 kg, use the 1½-inch, 22G needle (needle with gray hub).

For injections into the GLUTEAL MUSCLE:
Use the 1½-inch, 22G needle (needle with gray hub), regardless of patient body weight.

3. Hold the syringe with the tip pointing upward and remove the rubber cap with a gentle twisting motion.

4. Partially peel back the outer part of the safety-protected needle packaging. Grasp the needle shield through the packaging and securely attach the safety-protected needle to the syringe by gently screwing it on clockwise.

5. 1. Slide the needle safety guard toward the syringe. 2) Remove the needle shield with a straight pull. Do not twist the shield, as this may loosen the needle from the prefilled syringe.

6. Remove air from the prefilled syringe by gently pressing the plunger rod while holding the syringe vertically.

7. Inject the entire contents of the prefilled syringe intramuscularly, slowly and deeply, into the selected muscle—deltoid or gluteal. Do not administer the medicinal product intravenously or subcutaneously.

8. After completing the injection, activate the needle safety guard by pressing the shield with the thumb or finger of one hand (8a, 8b), or against a flat surface (8c). A click sound indicates that the needle has been properly secured. Dispose of the prefilled syringe with the needle properly.

Keep out of reach of children.
Any unused product or waste material should be disposed of in accordance with local regulations.